Spatial Genomics Uncovers Cytokines Promoting Ovarian Tumour Heterogeneity and Immunotherapy Resistance

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2025 Feb 23

PMID 39988560

Authors

Gurkan Mollaoglu

Brian D Brown

Alessia Baccarini

Affiliations

Soon will be listed here.

References

Ghisoni E, Morotti M, Sarivalasis A, Grimm A, Kandalaft L, Dangaj Laniti D . Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach. Nat Rev Clin Oncol. 2024; 21(11):801-817. DOI: 10.1038/s41571-024-00937-4. View

Mollaoglu G, Tepper A, Falcomata C, Potak H, Pia L, Amabile A . Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Cell. 2024; 187(26):7492-7510.e22. PMC: 11682930. DOI: 10.1016/j.cell.2024.10.006. View

Dhainaut M, Rose S, Akturk G, Wroblewska A, Nielsen S, Park E . Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell. 2022; 185(7):1223-1239.e20. PMC: 8992964. DOI: 10.1016/j.cell.2022.02.015. View

Konstantinopoulos P, Matulonis U . Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023; 4(9):1239-1257. DOI: 10.1038/s43018-023-00617-9. View

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

Zhai B, Tian H, Sun J, Zou J, Zhang X, Cheng J . Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. J Transl Med. 2022; 20(1):135. PMC: 8932206. DOI: 10.1186/s12967-022-03329-3. View

Veneziani A, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M . Heterogeneity and treatment landscape of ovarian carcinoma. Nat Rev Clin Oncol. 2023; 20(12):820-842. DOI: 10.1038/s41571-023-00819-1. View

Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5):541-550. PMC: 5998822. DOI: 10.1038/s41591-018-0014-x. View

Izar B, Tirosh I, Stover E, Wakiro I, Cuoco M, Alter I . A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020; 26(8):1271-1279. PMC: 7723336. DOI: 10.1038/s41591-020-0926-0. View

10.

Kandalaft L, Dangaj Laniti D, Coukos G . Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat Rev Cancer. 2022; 22(11):640-656. DOI: 10.1038/s41568-022-00503-z. View

11.

Desbois M, Udyavar A, Ryner L, Kozlowski C, Guan Y, Durrbaum M . Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nat Commun. 2020; 11(1):5583. PMC: 7642433. DOI: 10.1038/s41467-020-19408-2. View

12.

Mahmood N, Mihalcioiu C, Rabbani S . Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front Oncol. 2018; 8:24. PMC: 5816037. DOI: 10.3389/fonc.2018.00024. View

13.

Feng B, Bai Z, Zhou X, Zhao Y, Xie Y, Huang X . The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8 T cells against cancer. Nature. 2024; 634(8034):712-720. PMC: 11485240. DOI: 10.1038/s41586-024-07962-4. View

14.

Zhang A, McPherson A, Milne K, Kroeger D, Hamilton P, Miranda A . Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell. 2018; 173(7):1755-1769.e22. DOI: 10.1016/j.cell.2018.03.073. View

15.

Stewart C, Siegler E, Sakemura R, Cox M, Huynh T, Kimball B . IL-4 drives exhaustion of CD8 CART cells. Nat Commun. 2024; 15(1):7921. PMC: 11393358. DOI: 10.1038/s41467-024-51978-3. View

16.

Hornburg M, Desbois M, Lu S, Guan Y, Lo A, Kaufman S . Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell. 2021; 39(7):928-944.e6. DOI: 10.1016/j.ccell.2021.04.004. View

17.

Wroblewska A, Dhainaut M, Ben-Zvi B, Rose S, Park E, Amir E . Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens. Cell. 2018; 175(4):1141-1155.e16. PMC: 6319269. DOI: 10.1016/j.cell.2018.09.022. View

18.

LaMarche N, Hegde S, Park M, Maier B, Troncoso L, Le Berichel J . An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature. 2023; 625(7993):166-174. PMC: 11189607. DOI: 10.1038/s41586-023-06797-9. View

19.

Vazquez-Garcia I, Uhlitz F, Ceglia N, Lim J, Wu M, Mohibullah N . Ovarian cancer mutational processes drive site-specific immune evasion. Nature. 2022; 612(7941):778-786. PMC: 9771812. DOI: 10.1038/s41586-022-05496-1. View